ASH 2022:

• USA and UK report similar Patient-Reported Quality of Life in Sickle Cell: A Comparative Study.

  Sophie Lanzkron, Jane Little, Daniel Semakula, Jessica Liang, Sara Stuart-Smith, Rachel Kesse-Adu, Julie Kanter, Alice Cohen, Sana Saif Ur Rehman, Stephanie Guarino, Deepa Manwani, Payal Desai, Sheila Azouji-Benjamin, Abbie Wickham, Kate Gardner

EHA 2023:

• Ageing Impacts Hydroxycarbamide Dosing in Sickle Cell Disease

  Isabelle Doss, Rachel Kesse-Adu, Anietie Ekong, Sara Stuart-Smith, Arne De Kreuk, Sheila Azouji-Benjamin, Kate Gardner

• Prevalence and risk factors for retinopathy in sickle cell

  Rachel Kesse-Adu, Dale Seviar, Sara Stuart-Smith, Arne Dekreuk, Sheila Azouji-Benjamin, Kate Gardner

ASCAT 2023:

• Patient report quality of life measures in sickle cell:  a UK multi-center study

  Saima Afridi, Rachel Kesse-Adu, Dale Seviar, Sara Stuart Smith, Arne de Kreuk, Moji Awogbade, Matthew Player, Kate Gardner

• The Natural History and Clinical Outcomes in sickle cell disease: a multi-centre UK study

  Sheila Azouji-Benjamin, Rachel Kesse-Adu, Sara Stuart-Smith, Dale Seviar, Arne de Kreuk, Moji Awogbade, Kate Gardner 

ASH 2023:

• Natural history and clinical outcomes of patients with sickle cell disease: the burden of avascular necrosis in a British cohort

  Arne de Kreuk, Sara Stuart-Smith, Rachel Kesse-Adu, Dale Seviar, Moji Awogbade , Kate Gardner

EHA 2024:

• All-cause anaemia trumps degree of haemolysis as a determinant of quality of life: the UK multi-site sickle natural history study

  Jumoke Stella Okikiolu, Rachel Kesse-Adu, Sheila Azouji-Benjamin, Dale Seviar, Sara Stuart-Smith, Moji Awogbade, Arne de Kreuk, Matthew Player, Kate Gardner

• Factors limiting Hydroxycarbamide dosing in adults with SCD. Results from the UK’s Sickle Natural Study.
  Michael Neale, Sheila Azouji-Benjamin, Dale Seviar, Moji Awogbade, Arne Dekreuk, Matt Player, Sara Stuart-Smith, Kate Gardner, Rachel Kesse-Adu